XTL Biopharmaceuticals Ltd.

As of June 30, 2025, XTL Biopharmaceuticals Ltd. carries a market capitalization of 3.61B, placing it among publicly traded companies globally. Its enterprise value stands at 3.56B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2025, XTL Biopharmaceuticals Ltd. has 881.39M shares outstanding.

These figures are as of June 30, 2025.

As of June 30, 2025, XTL Biopharmaceuticals Ltd. maintains a current ratio of 0.70, meaning it holds 0.7x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2025.

As of the close on October 22, 2026, XTL Biopharmaceuticals Ltd.'s stock has declined approximately 65.12% over the past 52 weeks. The 50-day moving average sits at 1.85, while the 200-day moving average is 2.13.

As of June 30, 2025, XTL Biopharmaceuticals Ltd. holds 87.17M in cash and equivalents against 28.95M in total debt, resulting in a net debt position of -21.54M. Total book value stands at -15.82M, with working capital of -76.74M providing operational flexibility.

XTL Biopharmaceuticals Ltd.'s most recent stock split took place on June 23, 2009 with a 5:1 split ratio.